Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PTC moves muscular dystrophy drug into phase II
PTC124 is a novel, orally administered drug that targets nonsense mutations and is being investigated initially as a treatment for Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF),
PTC124 is a novel, orally administered drug that targets nonsense mutations and is being investigated initially as a treatment for Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF),
The compound, NRP104, is the subject of a collaborative development and commercialization agreement between New River and Shire. New River submitted the NDA on December 6, 2005. “We
Esophageal cancer is a difficult to treat disease, and only modest progress has been made in patient survival post-diagnosis during the past decade. In the study, 24 patients
SuperGen will pay the Montigen stockholders a total of $18 million upon the closing of the transaction, consisting of $9 million in cash and $9 million in shares
Orphan drug designation is awarded to potential treatments for rare and very serious conditions. The designation confers certain benefits such as market exclusivity for up to ten years
The study found that these women exhibited lower bone density and more fractures than women who did not have diabetes, even though those with diabetes were more likely
The results of the project could lead to major insights into the bird flu virus known as H5N1, the researchers said. The project produced 70 million bases of
The approval is a major boost for the company that has invested approximately $1 billion in the development of the drug. The company is presently awaiting a final
The amended agreement gives Merck global development and marketing rights to the vaccine except in Canada, where the companies share rights to the vaccine. Previously the companies shared
Phase III has issued five million shares of its common stock to NeoStem in exchange for certain assets, properties and rights that relate to NeoStem’s adult stem cell